AR065818A1 - Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana - Google Patents

Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Info

Publication number
AR065818A1
AR065818A1 ARP080101195A ARP080101195A AR065818A1 AR 065818 A1 AR065818 A1 AR 065818A1 AR P080101195 A ARP080101195 A AR P080101195A AR P080101195 A ARP080101195 A AR P080101195A AR 065818 A1 AR065818 A1 AR 065818A1
Authority
AR
Argentina
Prior art keywords
human
antibody
combinations
cancer
treatment
Prior art date
Application number
ARP080101195A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065818(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR065818A1 publication Critical patent/AR065818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de combinaciones de la IL-18 humana en el tratamiento de diversas formas de tumores solidos y linfomas. En particular, la presente se refiere a: (1) combinaciones de la IL-18 humana con anticuerpos monoclonales contra antígenos que se expresanen la superficie de células cancerosas; y (2) combinaciones de IL-18 humana con agentes terapéuticos. Reivindicacion 1: Un método para tratar el cáncer en un paciente necesitado de ello, que comprende la etapa de: administrar separadamente alpaciente una composicion que comprende: (1) un polipéptido (SEQ ID N°:1) de la IL-18 humana en combinacion con un vehículo y; y (ii) un anticuerpo monoclonal contra un antígeno que se expresa en la superficie de una célula cancerosa, en el que elanticuerpo tiene una funcion de efector de citotoxicidad dependiente de anticuerpos mediada por células (ADCC), y en el que el anticuerpo no es un anticuerpo anti-CD20. Reivindicacion 13: El método segun la reivindicacion 9, en el que el agentequimioterapéutico se elige del grupo de: doxil, topotecán, fármacos que alteran el DNA, carboplatino, antimetabolitos, gemcitabina, fármacos que impiden la division celular, vincristina, agentes antiangiogénicos, y pazopanib.
ARP080101195A 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana AR065818A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR065818A1 true AR065818A1 (es) 2009-07-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101155A AR065803A1 (es) 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080101155A AR065803A1 (es) 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Country Status (21)

Country Link
US (4) US20100111945A1 (es)
EP (3) EP2136841A4 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100014530A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231114A1 (es)
BR (2) BRPI0809079A2 (es)
CA (2) CA2681827A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970884A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31264B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118733A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2946796C (en) 2014-04-25 2019-10-22 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
PL3134124T3 (pl) 2014-04-25 2019-09-30 Pierre Fabre Medicament Koniugat przeciwciało IGF-IR-lek i jego zastosowanie do leczenia raka
JP6245622B2 (ja) * 2014-08-07 2017-12-13 学校法人兵庫医科大学 Ｉｌ−１８と分子標的抗体とを併用する癌治療薬
US10618970B2 (en) * 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
CZ20024085A3 (cs) 2000-06-15 2003-05-14 Smithkline Beecham Corporation Způsob přípravy fyziologicky aktivního IL-18 polypeptidu
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
CA2476776A1 (en) * 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
WO2004024180A1 (en) * 2002-09-16 2004-03-25 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
CA2501757C (en) * 2002-10-08 2012-04-24 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
ES2744275T3 (es) * 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ATE459647T1 (de) * 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
RU2412199C2 (ru) * 2005-04-18 2011-02-20 Ново Нордиск А/С Варианты ил-21
JP2009501913A (ja) * 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
WO2008008981A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CA2662609A1 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
EP2136841A4 (en) 2010-07-07
US20080274078A1 (en) 2008-11-06
EA200970885A1 (ru) 2010-02-26
SG171674A1 (en) 2011-06-29
CA2681851A1 (en) 2008-10-02
AR065803A1 (es) 2009-07-01
MX2009010271A (es) 2009-10-12
EP2129398A4 (en) 2010-04-21
EP2338514A1 (en) 2011-06-29
US20100111945A1 (en) 2010-05-06
EP2129398A1 (en) 2009-12-09
MA31265B1 (fr) 2010-03-01
CN101678102A (zh) 2010-03-24
DOP2009000220A (es) 2009-10-31
KR20100014530A (ko) 2010-02-10
CR10996A (es) 2009-11-12
BRPI0808943A2 (pt) 2014-08-26
AU2008231114A1 (en) 2008-10-02
CL2008000818A1 (es) 2008-09-26
BRPI0809079A2 (pt) 2019-03-06
NZ579179A (en) 2011-12-22
US20100196310A1 (en) 2010-08-05
IL200863A0 (en) 2010-05-17
TW200904469A (en) 2009-02-01
TW200906436A (en) 2009-02-16
PE20090184A1 (es) 2009-03-22
MX2009010269A (es) 2009-10-12
US20090035258A1 (en) 2009-02-05
JP2010522239A (ja) 2010-07-01
WO2008118736A1 (en) 2008-10-02
EA200970884A1 (ru) 2010-04-30
WO2008118733A2 (en) 2008-10-02
AU2008231025A1 (en) 2008-10-02
MA31264B1 (fr) 2010-03-01
CR11075A (es) 2010-03-22
CL2008000842A1 (es) 2008-10-17
KR20100015798A (ko) 2010-02-12
JP2010522200A (ja) 2010-07-01
IL200525A0 (en) 2010-04-29
CA2681827A1 (en) 2008-10-02
DOP2009000208A (es) 2010-03-31
WO2008118733A3 (en) 2008-11-27
PE20090190A1 (es) 2009-03-22
EP2136841A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
AR065818A1 (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
JP7295283B2 (ja) Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
Ronson et al. Treatment of relapsed/refractory acute lymphoblastic leukemia in adults
Sullivan-Chang et al. Targeting CD22 in B-cell malignancies: current status and clinical outlook
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20211915A1 (es) Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
BRPI0909227B8 (pt) uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
AR071733A1 (es) Terapia combinada de un anticuerpo anti-cd20 tipo ii con un inhibidor de proteasoma
PE20191328A1 (es) Conjugados de farmacos y anticuerpos anti-ccr7
WO2020092848A3 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
JP7250986B2 (ja) 細胞傷害性免疫刺激性粒子及びその使用
Ströhlein et al. The current status of immunotherapy in peritoneal carcinomatosis
JP2020504092A (ja) 薬物の治療可能性を改善するためのｏアセチル化ｇｄ２ガングリオシドに対する抗体の使用
WO2017137595A3 (en) Cancer treatment using nk cells
Raghani et al. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
MX2022007779A (es) Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.
WO2020176748A8 (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
CL2020002857A1 (es) Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096)
AR086738A1 (es) Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström
WO2024006925A3 (en) Dosing regimens for cd19-directed cancer immunotherapy
EA202191377A1 (ru) Способы дозирования модифицированных способами инженерии t-клеток для лечения b-клеточных злокачественных опухолей
MX2022000990A (es) Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal